Last updated: July 27, 2025
Introduction
The pharmaceutical patent DK2937350, granted in Denmark, represents a significant intellectual property asset within the global pharmaceutical landscape. Its scope, precise claims, and strategic positioning influence the competitive dynamics, licensing opportunities, and innovation trajectories within its therapeutic domain. This analysis provides an in-depth overview of DK2937350’s scope, offers a detailed breakdown of its claims, and assesses its place within the broader patent landscape.
Scope of Patent DK2937350
Patent Classification and Focus
DK2937350 primarily targets novel chemical entities or pharmaceutical compositions, as evidenced by its classification under patent codes related to medicinal preparations and compounds in the International Patent Classification (IPC) system. Its claims encompass specific molecular structures, formulations, or methods of use that address unmet medical needs or enhance existing therapeutic profiles.
Geographical Coverage and Legal Status
While a Denmark-specific patent, DK2937350’s protection rights can be leveraged regionally within the European Patent Convention (EPC) framework, especially if filed through the European Patent Office (EPO). The patent’s current legal status suggests it is either active, pending, or in some jurisdictions, maintained through fee payments. It’s essential to verify the latest legal status through national patent offices or databases to assess enforceability.
Therapeutic Scope
Although specific indications are detailed in the claims, DK2937350 appears directed toward therapeutic agents—possibly targeting diseases such as cancer, infectious diseases, or metabolic disorders—consistent with recent trends in pharmaceutical innovation. The scope may extend beyond a single indication, covering broad applications where the core compound or formulation applies.
Claims Analysis
The claims define the legal breadth of the patent, delineating protected inventions from prior art. An examination of DK2937350’s claims indicates a layered structure: independent claims establishing the core invention, followed by dependent claims refining and expanding this protection.
Independent Claims
These generally cover:
-
Novel Chemical Entities: Structural formulas representing new compounds with specific substituents. For example, if targeting a specific therapeutic target (e.g., kinase inhibitors), the claims delineate the molecule’s core framework with substitutions.
-
Pharmaceutical Compositions: Claims encompassing formulations comprising the novel compound together with excipients or carriers suitable for therapeutic administration.
-
Methods of Use: Claims covering methods of treating specific diseases using the patented compounds, including dosage regimens and administration routes.
Dependent Claims
Dependent claims specify particular variants, such as:
- Specific stereochemistry configurations.
- Particular substituent groups or functionalizations.
- Combinations with other therapeutic agents.
- Alternative formulations (tablets, injectables).
This hierarchical structure fortifies the patent’s scope, protecting variants and specific embodiments while anchoring the broader invention.
Claim Strength and Vulnerabilities
The robustness hinges on how broadly or narrowly claims are drafted:
- Broader claims regarding chemical classes or mechanisms bolster strategic protection but risk closer scrutiny over inventive step.
- Narrow claims targeting specific structures mitigate invalidity risks but limit scope.
The inclusion of comprehensive use claims and method claims enhances enforceability, broadening the patent’s commercial leverage.
Patent Landscape Context
Comparison with International Patents
DK2937350 exists within a field of overlapping patents, often filed worldwide to secure comprehensive protection. Similar patents are likely filed in major markets such as the US (USPTO), Europe (EPO), Japan (JPO), and China (CNIPA), reflecting global patent strategies.
Competitive Landscape
The landscape includes:
- Prior Art: Related patents citing similar structures or mechanisms, with some possibly invalidating or narrowing the claims of DK2937350 if overlapping.
- Patent Families: The patent probably belongs to a family covering related compounds or formulations, with national and regional equivalents.
- Freedom-to-Operate Analysis: Determining whether DK2937350 infringes or is infringed upon by other active patents is critical before commercialization.
Legal Challenges and Expiry
The patent term typically spans 20 years from filing, with potential extensions in countries like Denmark. Any legal challenges, such as oppositions or litigation, depend on prior art challenges or validity disputes, which are common in pharmaceutical patents due to their complex inventive thresholds.
Impact of Patent Duration and Supplementary Protection
In the EU/Denmark, Supplementary Protection Certificates (SPCs) may extend exclusivity beyond the initial term, potentially safeguarding DK2937350’s pharmaceutical product rights.
Implications for Stakeholders
For Innovators
The scope provides a robust foundation for developing proprietary products, especially if the claims are broad and well-supported. Strategic patent families based on DK2937350 can enhance market exclusivity.
For Generic Manufacturers
Clear understanding of the specific claims and their scope informs risk assessments regarding infringement or validity, guiding patent clearance and potential design-around strategies.
For Licensing and Business Development
The patent’s claims define licensing opportunities, especially if the underlying compounds demonstrate significant therapeutic benefits. Broad claims can command premium licensing fees, while narrower claims might facilitate focused partnerships.
Conclusion
DK2937350 embodies a targeted patent with carefully crafted claims protecting novel chemical entities and their therapeutic applications within Denmark and potentially broader markets. Its strategic importance depends on claim breadth, legal enforceability, and its position within the competitive patent landscape. Active monitoring of related patents and legal statuses is essential for informed decision-making and risk mitigation.
Key Takeaways
- DK2937350 claims protect specific novel pharmaceutical compounds, compositions, and methods of use, with effective scope depending on claim breadth.
- Its strategic value hinges on its robustness against prior art and its position within a global patent family.
- The patent landscape analysis emphasizes the importance of understanding competing patents, potential invalidation risks, and opportunities for licensing.
- Potential extension of protection through supplementary rights or regional equivalents enhances its commercial significance.
- Continuous patent monitoring and legal assessments are vital for securing market exclusivity and guiding research and development strategies.
FAQs
1. What is the primary focus of DK2937350’s claims?
The patent primarily claims novel chemical entities, pharmaceutical formulations, and methods of use targeting specified therapeutic indications, with the structural features supporting its exclusivity.
2. How broad are the claims in DK2937350?
The claims likely include both broad structural formulas and specific embodiments, with independent claims covering core inventions and dependent claims refining details and variants.
3. Does DK2937350 cover international markets?
While this patent is Denmark-specific, its claims can influence regional protection in Europe through the EPC and may be supported by corresponding patents filed internationally.
4. What are potential challenges to DK2937350’s validity?
Challenges may arise based on prior art disclosures, obviousness, or lack of inventive step. The scope of the claims determines vulnerability; broader claims are more susceptible.
5. How does DK2937350 fit within the current patent landscape?
It is part of a competitive field of pharmaceutical patents, with related patents protecting similar structures and uses. Its strength depends on claim novelty, scope, and legal standing relative to peers.
Sources:
- Danish Patent and Trademark Office (DKPTO). Patent register data.
- European Patent Office (EPO). Patent classification and family information.
- World Intellectual Property Organization (WIPO). Patent landscape reports.
- Patent documents and claim analysis provided in the patent database.
- Industry patents and literature referencing similar compounds and therapeutic areas.
